• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Firdapse (amifampridine)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Firdapse (amifampridine)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Firdapse (amifampridine) is a potassium channel blocker. 

    Firdapse is specifically indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

    Fiedapse is supplied as a tablet for oral administration. The recommended starting dosage is 15 mg to 30 mg daily, taken orally in divided doses (3 to 4 times daily). The dosage can be increased by 5 mg daily every 3 or 4 days. The maximum recommended total daily dosage is 80 mg. The maximum single dose is 20 mg. If a dose is missed, patients should not take double or extra doses. 

    Clinical Results

    FDA Approval

    The FDA approval of Firdapse was based on  two randomized, double-blind, placebo-controlled discontinuation studies. A total of 64 adults (age 21 to 88 years) with LEMS were enrolled (Study 1 and Study 2). Patients were required to be on an adequate and stable dosage (30 to 80 mg daily) of amifampridine phosphate prior to entering the randomized discontinuation phases of both studies. The two co-primary measures of efficacy in both studies were the change from baseline to the end of the discontinuation period in the Quantitative Myasthenia Gravis (QMG) score and in the Subject Global Impression (SGI) score. 

    Study 1: After an initial open-label run-in phase, 38 patients were randomized in a double-blind fashion to either continue treatment with Firdapse (n=16) or to a downward titration to placebo (n=22) over 7 days. Following the downward titration period, patients remained on blinded Firdapse or placebo for 7 more days. Efficacy was assessed at Day 14 of the double-blind period. Patients were allowed to use stable dosages of peripherally acting cholinesterase inhibitors or oral immunosuppressants. Twenty-six percent of patients randomized to Firdapse were receiving cholinesterase inhibitors, versus 36% in the placebo group, and 28% of patients randomized to Firdapse were receiving oral immunosuppressant therapies, versus 34% in the placebo group. During the double-blind period (from Baseline to Day 14), the QMG scores tended to worsen in both treatment groups, but there was significantly greater worsening in the placebo group than in the Firdapse group. Similarly, the SGI score tended to worsen in both treatment groups during the double-blind period, but there was significantly greater worsening in the placebo group than in the Firdapse group. These results indicate that in Study 1, patients randomized to placebo had a significantly greater worsening of muscle weakness and of global impression of the effects of the study treatment on their physical well-being, compared to patients who continued Firdapse in the double-blind period. 

    Study 2: Patients on stable treatment with Firdapse were randomized 1:1 in a double-blind fashion to either continue treatment with Firdapse (n=13) or change to placebo (n=13) for 4 days. Efficacy was assessed at the end of the 4-day double-blind discontinuation period. Patients were allowed to use stable doses of peripherally acting cholinesterase inhibitors or corticosteroids. From Baseline to Day 4, there was significantly greater worsening in the QMG score in the placebo group than in the Firdapse group, and also significantly greater worsening in the SGI score in the placebo group than in the Firdapse group. These results indicate that in Study 2, patients randomized to placebo had a significantly greater worsening of muscle weakness and of global impression of the effects of the study treatment on their physical well-being, compared to patients who continued Firdapse in the double-blind period.

    Side Effects

    Adverse effects associated with the use of Firdapse may include, but are not limited to, the following:

    paresthesia

    upper respiratory tract infection

    abdominal pain

    nausea

    diarrhea

    headache

    elevated liver enzymes

    back pain

    hypertension

    muscle spasms

    Mechanism of Action

    Firdapse (amifampridine) is a broad spectrum potassium channel blocker. The mechanism by which amifampridine exerts its therapeutic effect in LEMS patients has not been fully elucidated. 

    Additional Information

    For additional information regarding Lambert-Eaton myasthenic syndrome or Firdapse, please visit https://www.firdapse.com/

    Approval Date: 2018-11-01
    Company Name: Catalyst Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing